RE
PDSB icon

RBC Europe’s PDS Biotechnology PDSB Stock Holding History

RBC Europe’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,150
Closed -$91.6K – 993
2021
Q3 		$91.6K Hold
6,150
– – ﹤0.01% 435
2021
Q2 		$77.2K Buy
6,150
+1,500
+32% +$11.7K ﹤0.01% 488
2021
Q1 		$21.2K Buy
4,650
+1,400
+43% +$5.63K ﹤0.01% 746
2020
Q4 		$6.96K Hold
3,250
– – ﹤0.01% 927
2020
Q3 		$7.57K Buy
+3,250
New +$9.11K ﹤0.01% 849

Other funds holding PDSB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RBC Europe's PDSB Position: Q4 2021 in Review

RBC Europe sold out of PDS Biotechnology (PDSB) in Q4 2021, closing a stake of 6,150 shares — an estimated $91.6K sold.

RBC Europe first reported a position in PDSB in Q3 2020 and held it in 5 quarters. The position peaked at $91.6K in Q3 2021. 65 funds tracked by Wall St. Rank hold PDSB as of Q4 2021.

  • RBC Europe reported no remaining PDS Biotechnology position as of Q4 2021 after selling out during the quarter.
  • RBC Europe sold 6,150 PDS Biotechnology shares in Q4 2021, an estimated $91.6K.
  • RBC Europe first reported a position in PDS Biotechnology in Q3 2020 and held it in 5 quarters.
  • RBC Europe's PDS Biotechnology position peaked at $91.6K in Q3 2021.
  • 65 funds tracked by Wall St. Rank held PDS Biotechnology as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.